

7-5/2013/EU/WC-0142
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Koffa Road,
New Delhi-110002
Dated:

25 FEB 2022

To,

M/s. Cipla Limited,
Plot No. A-33, A-37/2/2 & A-2, MIDC,
Patalganga, Dist. Raigad-410 220
Maharashtra, India

SUB:- Written Confirmation of M/s. Cipla Limited, Plot No. A-33, A-37/2/2 & A-2, MIDC, Patalganga, Dist. Raigad-410 220 Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/ED/2021/707 submitted to CDSCO, West Zone office and the recommendation received from DDC(I), West Zone office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- 0 LC
1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
 2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.


Annexure No.	No. of Products	Date of Issue	Valid Upto
1	31	05.08.2019	04.08.2022
2	01	05.08.2019	04.08.2022
3	03	25 FEB 2022	04.08.2022

o/c

Yours faithfully,



(Dr. V. G. Somani)
Drugs Controller General (India)



24/02/2022



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. :

Annexure-3
WC-0142

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: **M/s. Cipla Limited,**
Plot No. A-33, A-37/2/2 & A-2, MIDC,
Patalganga, Dist. Raigad-410 220
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Cetirizine Hydrochloride USP	Manufacturing & Packing
2.	Daclatasvir Dihydrochloride IH	Manufacturing & Packing
3.	Rivastigmine Tartrate USP	Manufacturing & Packing

ITEM(S) Three (03) ONLY

JK The Written Confirmation remains valid until: 04.08.2022

Signature

24/02/2022

25 FEB 2022

Stamp of the authority and date



25 FEB 2022